GALT
insider transactionsGALECTIN THERAPEUTICS INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-212.4K
300 buy · 212.7K sell
Net value · 365d
-$821.0K
$810 in · $821.8K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
12
300 buy · 212.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
568 sh
Own +1%
-
Sell·S
Chief Medical Officer · 10b5-1
$1.8K
568 sh · $3.10
Own -100%
-
Exercise·M
Chief Medical Officer · 10b5-1
$699
568 sh · $1.23
Own New
-
Grant·A
Director
$0
60.0K sh
Own New
-
Buy·P
Director
$810
300 sh · $2.70
Own +0%
-
Grant·A
Director
$0
60.0K sh
Own New
-
Grant·A
Chief Medical Officer · 10b5-1
$0
100.0K sh
Own New
-
Grant·A
Chief Medical Officer · 10b5-1
$0
65.0K sh
Own New
-
Grant·A
Joel Lewis KEY
President and CEO · 10b5-1
$0
120.0K sh
Own New
-
Grant·A
Joel Lewis KEY
President and CEO · 10b5-1
$0
84.0K sh
Own New
-
Grant·A
Director
$0
60.0K sh
Own New
-
Grant·A
Director
$0
60.0K sh
Own New
-
Grant·A
Director
$0
60.0K sh
Own New
-
Grant·A
Director, 10% Owner
$0
60.0K sh
Own New
-
Grant·A
Director, 10% Owner
$40.0K
13.2K sh · $3.04
Own +0%
-
Grant·A
Director
$0
60.0K sh
Own New
-
Grant·A
Director
$0
60.0K sh
Own New
-
Grant·A
Jack W Callicutt KEY
Chief Financial Officer · 10b5-1
$0
100.0K sh
Own New
-
Grant·A
Jack W Callicutt KEY
Chief Financial Officer · 10b5-1
$0
65.0K sh
Own New
-
Grant·A
Director
$0
60.0K sh
Own New
-
Grant·A
Joel Lewis KEY
President and CEO
$0
91.0K sh
Own New
-
Sell·S
Joel Lewis KEY
President and CEO · 10b5-1
$134.9K
37.7K sh · $3.58
Own -4%
-
Sell·S
Chief Medical Officer · 10b5-1
$78.2K
21.4K sh · $3.65
Own -100%
-
Sell·S
Jack W Callicutt KEY
Chief Financial Officer · 10b5-1
$74.7K
20.4K sh · $3.67
Own -73%
-
Sell·S
Joel Lewis KEY
President and CEO · 10b5-1
$108.3K
27.7K sh · $3.91
Own -3%
-
Sell·S
Chief Medical Officer · 10b5-1
$99.4K
25.5K sh · $3.90
Own -54%
-
Sell·S
Jack W Callicutt KEY
Chief Financial Officer · 10b5-1
$100.3K
25.7K sh · $3.90
Own -48%
-
Exercise·M
Joel Lewis KEY
President and CEO · 10b5-1
$0
84.0K sh
Own New
-
Sell·S
Joel Lewis KEY
President and CEO · 10b5-1
$77.9K
18.6K sh · $4.20
Own -2%
-
Exercise·M
Joel Lewis KEY
President and CEO · 10b5-1
$0
84.0K sh
Own +10%
-
Sell·S
Chief Medical Officer · 10b5-1
$54.8K
13.1K sh · $4.20
Own -22%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
60.0K sh
Own New
-
Sell·S
Jack W Callicutt KEY
Chief Financial Officer · 10b5-1
$58.4K
13.9K sh · $4.20
Own -21%
-
Exercise·M
Jack W Callicutt KEY
Chief Financial Officer · 10b5-1
$0
60.0K sh
Own +788%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
60.0K sh
Own New
-
Exercise·M
Jack W Callicutt KEY
Chief Financial Officer · 10b5-1
$0
60.0K sh
Own New
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
8.1K sh
Own +25%
-
Sell·S
Chief Medical Officer · 10b5-1
$33.1K
8.1K sh · $4.07
Own -100%
-
Exercise·M
Chief Medical Officer · 10b5-1
$10.0K
8.1K sh · $1.23
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 26, 2026 | Khurram Jamil 10b5-1 | Exercise M | 568 | $0 |
| May 26, 2026 | Khurram Jamil 10b5-1 | Sell S | 568 | $1.8K |
| May 26, 2026 | Khurram Jamil 10b5-1 | Exercise M | 568 | $699 |
| Mar 12, 2026 | Henry Brem | Grant A | 60.0K | $0 |
| Feb 6, 2026 | Kary Eldred | Buy P | 300 | $810 |
| Jan 16, 2026 | Richard A. Zordani Jr. | Grant A | 60.0K | $0 |
| Jan 16, 2026 | Khurram Jamil 10b5-1 | Grant A | 100.0K | $0 |
| Jan 16, 2026 | Khurram Jamil 10b5-1 | Grant A | 65.0K | $0 |
| Jan 16, 2026 | Joel Lewis KEY 10b5-1 | Grant A | 120.0K | $0 |
| Jan 16, 2026 | Joel Lewis KEY 10b5-1 | Grant A | 84.0K | $0 |
| Jan 16, 2026 | Harold H. Shlevin | Grant A | 60.0K | $0 |
| Jan 16, 2026 | Gilbert S Omenn | Grant A | 60.0K | $0 |
| Jan 16, 2026 | Elissa J. Schwartz | Grant A | 60.0K | $0 |
| Jan 16, 2026 | Richard E Uihlein | Grant A | 60.0K | $0 |
| Jan 16, 2026 | Richard E Uihlein | Grant A | 13.2K | $40.0K |
| Jan 16, 2026 | Kevin D Freeman | Grant A | 60.0K | $0 |
| Jan 16, 2026 | Kary Eldred | Grant A | 60.0K | $0 |
| Jan 16, 2026 | Jack W Callicutt KEY 10b5-1 | Grant A | 100.0K | $0 |
| Jan 16, 2026 | Jack W Callicutt KEY 10b5-1 | Grant A | 65.0K | $0 |
| Jan 16, 2026 | Gilbert F Amelio | Grant A | 60.0K | $0 |
| Jan 16, 2026 | Joel Lewis KEY | Grant A | 91.0K | $0 |
| Jan 6, 2026 | Joel Lewis KEY 10b5-1 | Sell S | 37.7K | $134.9K |
| Jan 6, 2026 | Khurram Jamil 10b5-1 | Sell S | 21.4K | $78.2K |
| Jan 6, 2026 | Jack W Callicutt KEY 10b5-1 | Sell S | 20.4K | $74.7K |
| Jan 5, 2026 | Joel Lewis KEY 10b5-1 | Sell S | 27.7K | $108.3K |
| Jan 5, 2026 | Khurram Jamil 10b5-1 | Sell S | 25.5K | $99.4K |
| Jan 5, 2026 | Jack W Callicutt KEY 10b5-1 | Sell S | 25.7K | $100.3K |
| Jan 2, 2026 | Joel Lewis KEY 10b5-1 | Exercise M | 84.0K | $0 |
| Jan 2, 2026 | Joel Lewis KEY 10b5-1 | Sell S | 18.6K | $77.9K |
| Jan 2, 2026 | Joel Lewis KEY 10b5-1 | Exercise M | 84.0K | $0 |
| Jan 2, 2026 | Khurram Jamil 10b5-1 | Sell S | 13.1K | $54.8K |
| Jan 2, 2026 | Khurram Jamil 10b5-1 | Exercise M | 60.0K | $0 |
| Jan 2, 2026 | Jack W Callicutt KEY 10b5-1 | Sell S | 13.9K | $58.4K |
| Jan 2, 2026 | Jack W Callicutt KEY 10b5-1 | Exercise M | 60.0K | $0 |
| Jan 1, 2026 | Khurram Jamil 10b5-1 | Exercise M | 60.0K | $0 |
| Jan 1, 2026 | Jack W Callicutt KEY 10b5-1 | Exercise M | 60.0K | $0 |
| Dec 31, 2025 | Khurram Jamil 10b5-1 | Exercise M | 8.1K | $0 |
| Dec 31, 2025 | Khurram Jamil 10b5-1 | Sell S | 8.1K | $33.1K |
| Dec 31, 2025 | Khurram Jamil 10b5-1 | Exercise M | 8.1K | $10.0K |
About GALT insider trading
This page tracks insider transactions for GALECTIN THERAPEUTICS INC (GALT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.